InMed Pharmaceuticals (INM) 10% owner ADAR1 Capital Management bought 2,640 shares for $34.6K at $13.10
ADAR1 Capital Management, a 10% owner of InMed Pharmaceuticals (INM), bought 2,640 shares at an average price of $13.10, totaling $34.6K on Nov 5, 2026. Post-transaction, they held 98,297 shares indirectly. The purchase occurred after a 1-for-10 reverse stock split and before a merger that renamed the company Mentari Therapeutics (MTRI).
How this was made
The 30-second read
Why it matters
The insider purchase is a routine disclosure but confirms continued confidence from a major shareholder.
Market read
Minor insider activity with limited price impact; primarily of interest to existing shareholders.
What to watch
The reverse split and name change to Mentari Therapeutics could affect liquidity and future shareholder composition.
Background
InMed Pharmaceuticals completed a 1-for-10 reverse split and merged into Mentari Therapeutics, changing its ticker to MTRI.
Ticker impact
ADAR1 Capital Management, a 10% owner, purchased 2,640 shares at $13.10, increasing its holding to 98,297 shares after a reverse split and merger.
modest upward pressure as the insider adds to its stake
The transaction size ($34.6K) is modest, but the buyer is a significant shareholder; markets may view the buy as a confidence signal.
Market effects
Limited impact on the biotech sector; insider activity is routine after a merger.
No broader regional effect.
Minimal global relevance.
Counterpoint
The purchase may be a tactical move to maintain influence after the merger, not a strong bullish signal.
Key entities
- InvestorADAR1 Capital Management
10% owner of InMed Pharmaceuticals, reported a small open‑market purchase.
- CompanyInMed Pharmaceuticals
Biotech firm that recently merged and changed its name to Mentari Therapeutics.
